SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies

Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients,...

Descripción completa

Detalles Bibliográficos
Autores principales: Haggenburg, Sabine, Hofsink, Quincy, Rutten, Caroline E., Nijhof, Inger S., Hazenberg, Mette D., Goorhuis, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Inc. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674560/
https://www.ncbi.nlm.nih.gov/pubmed/36805887
http://dx.doi.org/10.1053/j.seminhematol.2022.11.001
Descripción
Sumario:Patients with hematologic conditions have a higher risk of severe COVID-19 and COVID-19-related death. This is related to immune deficiencies induced by hematologic conditions and/or the treatment thereof. Prospective vaccine immunogenicity studies have demonstrated that in the majority of patients, a 3-dose COVID-19 vaccination schedule leads to antibody concentrations comparable to levels obtained in healthy adults after a 2-dose schedule. In B cell depleted patients, humoral responses are poor, however vaccination did induce potent cellular immune responses. The effect of 3-dose vaccination schedules and COVID-19 booster vaccinations on the protection of patients with hematologic malignancies against severe COVID-19 and COVID-19 related death remains to be confirmed by population-based vaccine effectiveness studies.

Ejemplares similares